Josh Schimmer Joins Evercore ISI Research Team

NEW YORK, July 25, 2017

Evercore (NYSE: EVR) announced today that Josh Schimmer has joined the Evercore ISI Healthcare Research team, as a Senior Managing Director, launching Small and Mid-Cap Biotech research coverage.  He will also help expand coverage in Large-Cap Biotech. Dr. Schimmer was a runner up in the 2015 and 2016 Institutional Investor's All America Research Team for SMID Biotech.  Umer Raffat will continue to lead Evercore ISI's Large-Cap effort across Biotech, Pharma-Major and Specialty Pharma.   

Dr. Schimmer was most recently a Managing Director & Senior Research Analyst at Piper Jaffray, covering companies in the Biotech sector.  Prior to that, he was a Managing Director at Lazard Capital Markets and held research positions at Leerink Swann, Davidson Kempner and Cowen and Company.   

Ed Hyman, Evercore ISI's Founder and Chairman, said, "Evercore ISI is committed to providing our clients with the highest quality independent research analysis and advice, consistently investing in talent to best serve their needs. Josh brings exceptional talent and experience to our Healthcare team, adding materially to the value that we deliver in this strategically important sector."

Umer Raffat said, "Josh will be a very important addition to our biotech effort as we look to further build out our coverage and serve our clients with independent and insightful research."

Josh Schimmer said, "I'm thrilled to join the premiere independent equity research group on the Street, and look forward to providing clients with differentiated analysis of small, mid and select large-cap biotech companies."